{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:46:33Z","timestamp":1791413193594,"version":"4.3.3"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.maturitas.2017.08.004","type":"journal-article","created":{"date-parts":[[2017,8,7]],"date-time":"2017-08-07T19:00:26Z","timestamp":1502132426000},"page":"69-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Screening for familial cancer risk: Focus on breast cancer"],"prefix":"10.1016","volume":"105","author":[{"given":"Christine","family":"Rousset-Jablonski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Gompel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2017.08.004_bib0005","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaoncol.2015.0735","article-title":"The global burden of cancer 2013","volume":"1","author":"Global Burden of Disease Cancer Collaboration","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0010","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(01)06524-2","article-title":"Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58, 209 women with breast cancer and 101, 986 women without the disease","volume":"358","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"2001","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0015","series-title":"Familial Breast Cancer: Classification, Care and Managing Breast Cancer and Related Risks in People with a Family History of Breast C","first-page":"cg164","author":"National Institute foe Helth and Excellence (NICE)","year":"2013"},{"key":"10.1016\/j.maturitas.2017.08.004_bib0020","series-title":"NCCN Clinical Practice Guidelines in Oncology: Genetic\/Familial High-Risk Assessment: Breast and Ovarian \u2013 Version 2.2017","author":"National Comprehensive Cancer Network (NCCN)","year":"2016"},{"key":"10.1016\/j.maturitas.2017.08.004_bib0025","series-title":"D\u00e9pistage du cancer de sein en France: identification des femmes \u00e0 haut risque et modalit\u00e9s de d\u00e9pistage","author":"Haute Autorit\u00e9 de Sant\u00e9 (HAS)","year":"2014"},{"key":"10.1016\/j.maturitas.2017.08.004_bib0030","first-page":"11","article-title":"Consortium of Investigators of Modifiers of BRCA1\/2, Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1\/2 (CIMBA)","volume":"21","author":"Mavaddat","year":"2012","journal-title":"Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol"},{"key":"10.1016\/j.maturitas.2017.08.004_bib0035","first-page":"219","article-title":"[Identification and management of hereditary predisposition to cancer of the breast and the ovary (update 2004)]","volume":"91","author":"Eisinger","year":"2004","journal-title":"Bull. Cancer (Paris)."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0040","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5","article-title":"Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction","volume":"73","author":"Claus","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.maturitas.2017.08.004_bib0045","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/sim.1668","article-title":"A breast cancer prediction model incorporating familial and personal risk factors","volume":"23","author":"Tyrer","year":"2004","journal-title":"Stat. Med."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0050","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1086\/301670","article-title":"Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2","volume":"62","author":"Parmigiani","year":"1998","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0055","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/sj.bjc.6604305","article-title":"The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions","volume":"98","author":"Antoniou","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.maturitas.2017.08.004_bib0060","first-page":"979","article-title":"[Estimation of individual breast cancer risk: relevance and limits of risk estimation models]","volume":"96","author":"De Pauw","year":"2009","journal-title":"Bull. Cancer (Paris)"},{"key":"10.1016\/j.maturitas.2017.08.004_bib0065","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/jnci\/91.18.1541","article-title":"Validation studies for models projecting the risk of invasive and total breast cancer incidence","volume":"91","author":"Costantino","year":"1999","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0070","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/annonc\/mdv022","article-title":"Genetics of breast cancer: a topic in evolution","volume":"26","author":"Shiovitz","year":"2015","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0075","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.ajpath.2013.07.003","article-title":"Inherited genetic susceptibility to breast cancer: the beginning of the end or the end of the beginning?","volume":"183","author":"Ghoussaini","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0080","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.breast.2016.10.024","article-title":"Effect on perceived control and psychological distress of genetic knowledge in women with breast cancer receiving a BRCA1\/2 test result","volume":"31","author":"Br\u00e9dart","year":"2017","journal-title":"Breast Edinb Scotl."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0085","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/pon.1864","article-title":"Opening the psychological black box in genetic counseling. The psychological impact of DNA testing is predicted by the counselees\u00f3 perception, the medical impact by the pathogenic or uninformative BRCA1\/2-result","volume":"21","author":"Vos","year":"2012","journal-title":"Psychooncology"},{"key":"10.1016\/j.maturitas.2017.08.004_bib0090","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0095","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"EMBRACE, cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE","volume":"105","author":"Mavaddat","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0100","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0105","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jama.2014.5985","article-title":"Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer","volume":"313","author":"Rebbeck","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2017.08.004_bib0110","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Cancer Genome Atlas Research Network, Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2017.08.004_bib0115","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10689-011-9506-2","article-title":"Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations","volume":"11","author":"Moran","year":"2012","journal-title":"Fam. Cancer."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0120","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/jmg.2009.075176","article-title":"Risk of breast cancer in male BRCA2 carriers","volume":"47","author":"Evans","year":"2010","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0125","unstructured":"INCa (Institut National du Cancer), Femmes porteuses d\u2019une mutation de BRCA1 ou BRCA2. D\u00e9tection pr\u00e9coce du cancer du sein et des annexes et strat\u00e9gies de r\u00e9duction du risque., (2017)."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0130","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1200\/JCO.2009.27.2294","article-title":"BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study","volume":"28","author":"Rijnsburger","year":"2010","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0135","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1200\/JCO.2009.23.0839","article-title":"Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial","volume":"28","author":"Kuhl","year":"2010","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0140","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2009.27.0835","article-title":"Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging","volume":"29","author":"Warner","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0145","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/bjc.2012.204","article-title":"Long-term results of screening with magnetic resonance imaging in women with BRCA mutations","volume":"107","author":"Passaperuma","year":"2012","journal-title":"Br. J. Cancer."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0150","first-page":"1458","article-title":"Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined, Cancer Epidemiol","volume":"21","author":"Heijnsdijk","year":"2012","journal-title":"Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0155","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3109\/09553002.2011.608410","article-title":"DNA double-strand breaks induced by mammographic screening procedures in human mammary epithelial cells","volume":"87","author":"Colin","year":"2011","journal-title":"Int. J. Radiat. Biol."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0160","doi-asserted-by":"crossref","first-page":"e5660","DOI":"10.1136\/bmj.e5660","article-title":"Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1\/2 mutations: retrospective cohort study (GENE-RAD-RISK)","volume":"345","author":"Pijpe","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.maturitas.2017.08.004_bib0165","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/djn440","article-title":"Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers","volume":"101","author":"Berrington de Gonzalez","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0170","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/SLA.0b013e3181c3c36d","article-title":"Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer","volume":"251","author":"Kaas","year":"2010","journal-title":"Ann. Surg."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0175","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1399-0004.2010.01604.x","article-title":"Breast cancer after bilateral risk-reducing mastectomy","volume":"79","author":"Skytte","year":"2011","journal-title":"Clin. Genet."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0180","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/ijc.24038","article-title":"Time to stop ovarian cancer screening in BRCA1\/2 mutation carriers?","volume":"124","author":"van der Velde","year":"2009","journal-title":"Int. J. Cancer."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0185","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/jmg.2008.058248","article-title":"Screening for familial ovarian cancer: poor survival of BRCA1\/2 related cancers","volume":"46","author":"Evans","year":"2009","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0190","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1002\/cncr.30248","article-title":"Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort","volume":"122","author":"Mai","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.maturitas.2017.08.004_bib0195","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1200\/JCO.2014.59.5728","article-title":"Revisiting Li-Fraumeni syndrome from TP53 mutation carriers","volume":"33","author":"Bougeard","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0200","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/jmedgenet-2012-101339","article-title":"French Cowden Disease Network, High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome","volume":"50","author":"Bubien","year":"2013","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0205","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/jnci\/djr065","article-title":"Lifetime risk of selected cancers for people with Cowden syndrome","volume":"103","author":"StatBite","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0210","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1136\/gut.2009.198499","article-title":"Peutz-Jeghers syndrome: a systematic review and recommendations for management","volume":"59","author":"Beggs","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.maturitas.2017.08.004_bib0215","article-title":"NCCN clinical practice guidelines in oncology .Genetic\/Familial high-Risk assessment","author":"National Comprehensive Cancer Network (NCCN)","year":"2017","journal-title":"Colorectal"},{"key":"10.1016\/j.maturitas.2017.08.004_bib0220","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa1400382","article-title":"Breast-cancer risk in families with mutations in PALB2","volume":"371","author":"Antoniou","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2017.08.004_bib0225","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrclinonc.2016.90","article-title":"Counselling framework for moderate-penetrance cancer-susceptibility mutations","volume":"13","author":"Tung","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512217307831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512217307831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:12:08Z","timestamp":1759914728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512217307831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":45,"alternative-id":["S0378512217307831"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2017.08.004","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Screening for familial cancer risk: Focus on breast cancer","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2017.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}